AstraZeneca PLC (OTCMKTS:AZNCF) Short Interest Up 248.8% in November

AstraZeneca PLC (OTCMKTS:AZNCF) saw a significant increase in short interest in the month of November. As of November 15th, there was short interest totalling 147,200 shares, an increase of 248.8% from the October 31st total of 42,200 shares. Based on an average daily volume of 3,800 shares, the short-interest ratio is currently 38.7 days.

Institutional Trading of AstraZeneca

An institutional investor recently bought a new position in AstraZeneca stock. Kennedy Capital Management LLC acquired a new stake in shares of AstraZeneca PLC (OTCMKTS:AZNCF) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 37,554 shares of the company’s stock, valued at approximately $5,068,000. 40.87% of the stock is currently owned by institutional investors and hedge funds.

AstraZeneca Stock Performance

OTCMKTS:AZNCF traded up $3.34 during trading hours on Friday, reaching $134.70. 791 shares of the company were exchanged, compared to its average volume of 2,655. The stock has a 50 day simple moving average of $143.43 and a 200 day simple moving average of $153.97. AstraZeneca has a 52-week low of $118.16 and a 52-week high of $175.00.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.